Annual Cash & Cash Equivalents
$13.27 M
-$10.51 M-44.19%
December 31, 2023
Summary
- As of February 7, 2025, FENC annual cash & cash equivalents is $13.27 million, with the most recent change of -$10.51 million (-44.19%) on December 31, 2023.
- During the last 3 years, FENC annual cash & cash equivalents has fallen by -$17.07 million (-56.27%).
- FENC annual cash & cash equivalents is now -56.27% below its all-time high of $30.34 million, reached on December 31, 2020.
Performance
FENC Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$40.32 M
-$2.73 M-6.35%
September 30, 2024
Summary
- As of February 7, 2025, FENC quarterly cash and cash equivalents is $40.32 million, with the most recent change of -$2.73 million (-6.35%) on September 30, 2024.
- Over the past year, FENC quarterly cash and cash equivalents has dropped by -$2.73 million (-6.35%).
- FENC quarterly cash and cash equivalents is now -21.23% below its all-time high of $51.18 million, reached on March 31, 2024.
Performance
FENC Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
FENC Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -44.2% | -6.3% |
| 3 y3 years | -56.3% | +119.3% |
| 5 y5 years | -41.8% | +119.3% |
FENC Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -44.2% | at low | -21.2% | +225.2% |
| 5 y | 5-year | -56.3% | at low | -21.2% | +307.2% |
| alltime | all time | -56.3% | >+9999.0% | -21.2% | >+9999.0% |
Fennec Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $40.32 M(-6.4%) |
| Jun 2024 | - | $43.05 M(-15.9%) |
| Mar 2024 | - | $51.18 M(+285.7%) |
| Dec 2023 | $13.27 M(-44.2%) | $13.27 M(+7.0%) |
| Sep 2023 | - | $12.40 M(-17.1%) |
| Jun 2023 | - | $14.96 M(-18.7%) |
| Mar 2023 | - | $18.39 M(-22.6%) |
| Dec 2022 | $23.77 M(+12.7%) | $23.77 M(-20.1%) |
| Sep 2022 | - | $29.75 M(+99.5%) |
| Jun 2022 | - | $14.91 M(-18.3%) |
| Mar 2022 | - | $18.26 M(-13.5%) |
| Dec 2021 | $21.10 M(-30.5%) | $21.10 M(-13.3%) |
| Sep 2021 | - | $24.34 M(-10.8%) |
| Jun 2021 | - | $27.29 M(+2.0%) |
| Mar 2021 | - | $26.75 M(-11.8%) |
| Dec 2020 | $30.34 M(+122.3%) | $30.34 M(-8.5%) |
| Sep 2020 | - | $33.17 M(-14.4%) |
| Jun 2020 | - | $38.73 M(+291.2%) |
| Mar 2020 | - | $9.90 M(-27.5%) |
| Dec 2019 | $13.65 M(-40.1%) | $13.65 M(-10.4%) |
| Sep 2019 | - | $15.24 M(-12.8%) |
| Jun 2019 | - | $17.48 M(-13.6%) |
| Mar 2019 | - | $20.23 M(-11.2%) |
| Dec 2018 | $22.78 M(-19.4%) | $22.78 M(-7.1%) |
| Sep 2018 | - | $24.52 M(-4.4%) |
| Jun 2018 | - | $25.64 M(-4.0%) |
| Mar 2018 | - | $26.72 M(-5.5%) |
| Dec 2017 | $28.26 M(+619.8%) | $28.26 M(+191.7%) |
| Sep 2017 | - | $9.69 M(-5.3%) |
| Jun 2017 | - | $10.23 M(+214.7%) |
| Mar 2017 | - | $3.25 M(-17.2%) |
| Dec 2016 | $3.93 M(+316.8%) | $3.93 M(-13.5%) |
| Sep 2016 | - | $4.54 M(-10.7%) |
| Jun 2016 | - | $5.08 M(+832.3%) |
| Mar 2016 | - | $545.00 K(-42.1%) |
| Dec 2015 | $942.00 K(-59.2%) | $942.00 K(-31.0%) |
| Sep 2015 | - | $1.37 M(-26.3%) |
| Jun 2015 | - | $1.85 M(-3.2%) |
| Mar 2015 | - | $1.92 M(-16.9%) |
| Dec 2014 | $2.31 M(+38.7%) | $2.31 M(+289.0%) |
| Sep 2014 | - | $593.00 K(-41.6%) |
| Jun 2014 | - | $1.01 M(-24.1%) |
| Mar 2014 | - | $1.34 M(-19.5%) |
| Dec 2013 | $1.66 M(-27.8%) | $1.66 M(+209.1%) |
| Sep 2013 | - | $538.00 K(-46.6%) |
| Jun 2013 | - | $1.01 M(-46.9%) |
| Mar 2013 | - | $1.90 M(-17.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $2.30 M(-56.5%) | $2.30 M(-19.5%) |
| Sep 2012 | - | $2.86 M(-20.2%) |
| Jun 2012 | - | $3.59 M(-24.0%) |
| Mar 2012 | - | $4.72 M(-10.9%) |
| Dec 2011 | $5.30 M(-10.9%) | $5.30 M(-14.2%) |
| Sep 2011 | - | $6.17 M(-9.3%) |
| Jun 2011 | - | $6.81 M(+35.6%) |
| Mar 2011 | - | $5.02 M(-15.5%) |
| Dec 2010 | $5.95 M(+768.2%) | $5.95 M(-9.9%) |
| Sep 2010 | - | $6.60 M(-7.7%) |
| Jun 2010 | - | $7.15 M(+1955.2%) |
| Mar 2010 | - | $348.00 K(-49.2%) |
| Dec 2009 | $685.00 K(-87.3%) | $685.00 K(-21.1%) |
| Sep 2009 | - | $868.00 K(-43.6%) |
| Jun 2009 | - | $1.54 M(-49.5%) |
| Mar 2009 | - | $3.05 M(-43.6%) |
| Dec 2008 | $5.40 M(-66.6%) | $5.40 M(-31.5%) |
| Sep 2008 | - | $7.88 M(-24.1%) |
| Jun 2008 | - | $10.38 M(-22.0%) |
| Mar 2008 | - | $13.30 M(-17.7%) |
| Dec 2007 | $16.16 M(+185.3%) | $16.16 M(+21.5%) |
| Sep 2007 | - | $13.31 M(-35.4%) |
| Jun 2007 | - | $20.61 M(-8.3%) |
| Mar 2007 | - | $22.47 M(+296.6%) |
| Dec 2006 | $5.67 M(-52.5%) | $5.67 M(-36.7%) |
| Sep 2006 | - | $8.95 M(-27.0%) |
| Jun 2006 | - | $12.27 M(+29.0%) |
| Mar 2006 | - | $9.51 M(-20.2%) |
| Dec 2005 | $11.92 M(-12.8%) | $11.92 M(-9.5%) |
| Sep 2005 | - | $13.17 M(+4.9%) |
| Jun 2005 | - | $12.55 M(-14.6%) |
| Mar 2005 | - | $14.70 M(+21.3%) |
| Sep 2004 | - | $12.12 M(-11.4%) |
| Jun 2004 | $13.67 M(+535.5%) | $13.67 M(-3.6%) |
| Mar 2004 | - | $14.18 M(-14.4%) |
| Dec 2003 | - | $16.57 M(+1636.1%) |
| Sep 2003 | - | $954.30 K(-55.6%) |
| Jun 2003 | $2.15 M(+938.4%) | $2.15 M(+121.7%) |
| Mar 2003 | - | $970.30 K(-61.0%) |
| Dec 2002 | - | $2.49 M(-44.2%) |
| Sep 2002 | - | $4.45 M(+2049.3%) |
| Jun 2002 | $207.20 K(-97.8%) | $207.20 K(-96.8%) |
| Mar 2002 | - | $6.57 M(-9.6%) |
| Dec 2001 | - | $7.26 M(-10.3%) |
| Sep 2001 | - | $8.10 M(-13.4%) |
| Jun 2001 | $9.35 M(+8316.7%) | $9.35 M(+77.5%) |
| Dec 2000 | - | $5.27 M |
| Jun 2000 | $111.10 K | - |
FAQ
- What is Fennec Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Fennec Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Fennec Pharmaceuticals?
- What is Fennec Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Fennec Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of FENC is $13.27 M
What is the all time high annual cash & cash equivalents for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high annual cash & cash equivalents is $30.34 M
What is Fennec Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, FENC annual cash & cash equivalents has changed by -$10.51 M (-44.19%)
What is Fennec Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of FENC is $40.32 M
What is the all time high quarterly cash and cash equivalents for Fennec Pharmaceuticals?
Fennec Pharmaceuticals all-time high quarterly cash and cash equivalents is $51.18 M
What is Fennec Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, FENC quarterly cash and cash equivalents has changed by -$2.73 M (-6.35%)